Glioblastoma is the most common and aggressive brain tumor in adults. Despite surgery, radiation, and chemotherapy, survival rates remain low, which emphasizes the urgent need for improved therapies. Current preclinical models use untreated tumors, which do not reflect the clinical scenario where patients already receive initial treatments. This review examines the effects of current treatments on the properties of recurrent tumors and evaluates preclinical models that incorporate these standard treatments to better mimic real patient conditions. Improving these models could help to identify more effective treatments, potentially leading to better outcomes for glioblastoma patients.
Brayden featured in UKNow for CURE Fellowship
UKNow recently featured Brayden’s selection for the 2026 Commonwealth Undergraduate Research Experience (CURE) Fellowship program. As part of the fellowship, Brayden will conduct summer research in the BHL and present his work at the Summer Research Symposium on August 25. You can read the full story HERE.
May 22, 2026
